The progression of cancer requires mutational adaptation to permit unrestrained proliferation. A fraction of cancer mutations are oncogenic drivers, while others are putative ‘passengers’ that do not contribute to oncogenesis. However, altered peptides arising from passenger mutations may bind MHCs and activate non-self immunologic signals (i.e. neoantigens), thus requiring immunoediting for cancer persistence. Disruption of antigen processing machinery in tumor cells may diminish this requirement. Here, we show that rare mutations in antigen processing machinery are associated with high mutational burden and increased predicted neoantigen load, providing insights into the mechanisms of high mutation burden in some patients
MHC-I molecules expose the intracellular protein content on the cell surface, allowing T cells ...
Cancer is driven by somatic mutations that result in a cellular fitness advantage. This selective ad...
BackgroundImmune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associa...
BackgroundThe major histocompatibility complex class I (MHC-I) molecule is a protein complex that di...
Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expr...
The immune system can recognize and attack cancer cells, especially those with a high load of mutati...
Cancer is a complex and heterogeneous disease that can sometimes be effectively targeted with precis...
Somatic mutations can result in the formation of neoantigens, immunogenic peptides that are presente...
Somatic mutations can result in the formation of neoantigens, immunogenic peptides that are presente...
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are r...
Cancer is driven by somatic mutations that result in a cellular fitness advantage. This selective ad...
The somatic co-evolution of tumors and the cellular immune responses that combat them drives the div...
Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. Howe...
Background: Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by...
Next-generation sequencing technologies have revolutionized our ability to catalog the landscape of ...
MHC-I molecules expose the intracellular protein content on the cell surface, allowing T cells ...
Cancer is driven by somatic mutations that result in a cellular fitness advantage. This selective ad...
BackgroundImmune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associa...
BackgroundThe major histocompatibility complex class I (MHC-I) molecule is a protein complex that di...
Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially enabling the expr...
The immune system can recognize and attack cancer cells, especially those with a high load of mutati...
Cancer is a complex and heterogeneous disease that can sometimes be effectively targeted with precis...
Somatic mutations can result in the formation of neoantigens, immunogenic peptides that are presente...
Somatic mutations can result in the formation of neoantigens, immunogenic peptides that are presente...
Immunotherapies can mediate regression of human tumors with high mutation rates, but responses are r...
Cancer is driven by somatic mutations that result in a cellular fitness advantage. This selective ad...
The somatic co-evolution of tumors and the cellular immune responses that combat them drives the div...
Cancer somatic mutations can generate neoantigens that distinguish malignant from normal cells. Howe...
Background: Neoantigens that arise as a consequence of tumor-specific mutations can be recognized by...
Next-generation sequencing technologies have revolutionized our ability to catalog the landscape of ...
MHC-I molecules expose the intracellular protein content on the cell surface, allowing T cells ...
Cancer is driven by somatic mutations that result in a cellular fitness advantage. This selective ad...
BackgroundImmune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associa...